RGEN vs FTRE

For growth investors, Repligen Corporation (RGEN) is the stronger pick with 16.

4% revenue growth year-over-year, versus 1. 0% for Fortrea Holdings Inc. (FTRE). Repligen Corporation (RGEN) offers the better valuation at 146. 2x trailing P/E (63. 9x forward), making it the more compelling value choice. Analysts rate Repligen Corporation (RGEN) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Fortrea Holdings Inc.

is actually cheaper at 23. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Repligen Corporation (RGEN) delivered a total return of -32.

1%, compared to -51. 1% for Fortrea Holdings Inc. (FTRE). Over 10 years, the gap is even starker: RGEN returned +379. 1% versus FTRE's -51. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Repligen Corporation (RGEN) is the lower-risk stock at 1.

76β versus Fortrea Holdings Inc. 's 2. 35β — meaning FTRE is approximately 34% more volatile than RGEN relative to the S&P 500. On balance sheet safety, Fortrea Holdings Inc. (FTRE) carries a lower debt/equity ratio of 12% versus 33% for Repligen Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Repligen Corporation (RGEN) is pulling ahead at 16.

4% versus 1. 0% for Fortrea Holdings Inc. (FTRE). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -194. 6% for Fortrea Holdings Inc.. Over a 3-year CAGR, FTRE leads at -1. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Repligen Corporation (RGEN) is the more profitable company, earning 6.

6% net margin versus -36. 2% for Fortrea Holdings Inc. — meaning it keeps 6. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RGEN leads at 8. 1% versus -1. 1% for FTRE. At the gross margin level — before operating expenses — RGEN leads at 47. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Fortrea Holdings Inc.

(FTRE) trades at 23. 1x forward P/E versus 63. 9x for Repligen Corporation — 40. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RGEN: 33. 6% to $168. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Repligen Corporation (RGEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+379.

1% 10Y return). Fortrea Holdings Inc. (FTRE) carries a higher beta of 2. 35 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RGEN: +379. 1%, FTRE: -51. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RGEN is a small-cap high-growth stock; FTRE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.